STOCK TITAN

CSW Industrials (CSW) CEO sells 1,500 shares under 10b5-1 plan

(Very High)
(Negative)
Form Type
4

Rhea-AI Filing Summary

CSW INDUSTRIALS, INC. Chairman, President & CEO Joseph B. Armes reported a sale of 1,500 shares of Common Stock on 2026-08-14 at a weighted average price of $345.1574 per share, executed pursuant to a Rule 10b5-1 trading plan established on August 12, 2025. Following this sale, he directly holds 64,236 Common shares, plus 3,219 shares held indirectly by ESOP. He also holds performance rights tied to 9,836, 8,004, 8,236, and 9,186 underlying Common shares and 19,685 restricted stock units, all of which vest based on multi‑year performance or CEO‑succession conditions.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Armes Joseph B
Role Chairman, President & CEO
Sold 1,500 shs ($518K)
Type Security Shares Price Value
Sale Common Stock F1, F2 1,500 $345.1574 $518K
holding Performance Rights F3 -- -- --
holding Performance Rights F4 -- -- --
holding Performance Rights F5 -- -- --
holding Performance Rights F6 -- -- --
holding Restricted Stock Units F7 -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 64,236 shares (Direct); Performance Rights — 35,262 shares (Direct); Restricted Stock Units — 19,685 shares (Direct); Common Stock — 3,219 shares (Indirect, by ESOP)
Footnotes (7)
  1. F1. The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 12, 2025.
  2. F2. The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $342.75 to $346.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3. Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 250% during a three-year performance cycle beginning on April 1, 2026 and ending on March 31, 2029 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
  4. F4. Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2025, and ending on March 31, 2028, based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
  5. F5. Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2024, and ending on March 31, 2027, based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
  6. F6. Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200%, during a performance cycle beginning April 1, 2021 and ending on March 31, 2027 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
  7. F7. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at vesting. 40% of the restricted stock units vest no earlier than April 26, 2025 upon the successful recruitment and hiring of a successor Chief Executive Officer; the remaining 60% vest upon the successful first employment anniversary of a successor Chief Executive Officer.
Shares sold 1,500 shares Common Stock sale on 2026-08-14 by Joseph B. Armes
Weighted average sale price $345.1574 per share Common Stock sale on 2026-08-14
Direct Common shares after sale 64,236 shares Direct ownership following the 2026-08-14 sale
Indirect ESOP shares 3,219 shares Common Stock held indirectly by ESOP
Performance rights underlying shares (grant F3) 9,836 shares Performance rights beginning April 1, 2026, three-year cycle
Performance rights underlying shares (grant F4) 8,004 shares Performance rights beginning April 1, 2025, three-year cycle
Performance rights underlying shares (grant F5) 8,236 shares Performance rights beginning April 1, 2024, three-year cycle
Restricted stock units underlying shares 19,685 shares RSUs vesting upon CEO succession-related milestones
Rule 10b5-1 trading plan regulatory
"The transaction reported was effected pursuant to a 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
performance right financial
"Each performance right represents a contingent right to receive one share"
restricted stock unit financial
"Each restricted stock unit represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
relative total shareholder return financial
"based on the issuer's relative total shareholder return in comparison"
Relative total shareholder return measures how much an investor’s gain from a company — including stock price changes and dividends — beats or lags a chosen benchmark or peer group over a set time. Think of it as a race: it shows whether the company outpaced rivals or the market, which helps investors and boards judge performance, compare returns fairly, and link results to pay or investment decisions.
Russell 2000 Index financial
"among the Russell 2000 Index over the performance cycle"
A stock-market benchmark that tracks about 2,000 small-cap U.S. companies, the Russell 2000 gives a snapshot of how smaller publicly traded firms are performing. Investors use it like a thermometer or yardstick for the small-company segment of the market—funds and portfolio managers compare returns to it, and its movements can signal changes in economic risk appetite or growth expectations; it is weighted so larger small companies have a bigger influence on the index.

FAQ

What insider transaction did CSW (CSW) report for Joseph B. Armes?

Joseph B. Armes reported a sale of 1,500 shares of CSW Common Stock on 2026-08-14 at a weighted average price of $345.1574 per share. This was disclosed as a non-derivative open-market or private sale transaction.

Was the CSW (CSW) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan established by Joseph B. Armes on August 12, 2025. Such pre-arranged plans allow trades under preset instructions, independent of later information.

How many CSW (CSW) shares does Joseph B. Armes hold after the reported sale?

After the reported transaction, Joseph B. Armes directly holds 64,236 shares of CSW Common Stock. He also has an additional 3,219 shares held indirectly through an ESOP, plus various performance rights and restricted stock units tied to additional underlying shares.

What equity incentives in CSW (CSW) does Joseph B. Armes currently have?

He holds performance rights over 9,836, 8,004, 8,236, and 9,186 underlying CSW Common shares, and 19,685 restricted stock units. These awards vest over multi-year performance cycles or upon specified CEO succession milestones, potentially settling in cash or shares.

How is vesting of CSW (CSW) performance rights for Joseph B. Armes determined?

Each performance right represents a contingent right to one CSW Common share and vests between 0% and up to 250% depending on relative total shareholder return versus the Russell 2000 Index over defined three-year performance cycles.

What are the vesting conditions of Joseph B. Armes’ restricted stock units in CSW (CSW)?

Each restricted stock unit represents a contingent right to one CSW Common share. 40% of the 19,685 RSUs vest after recruitment and hiring of a successor CEO, and the remaining 60% vest upon that successor CEO’s first employment anniversary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Armes Joseph B

(Last)(First)(Middle)
5420 LYNDON B JOHNSON FWY
STE. 500

(Street)
DALLAS TEXAS 75240-1007

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CSW INDUSTRIALS, INC. [ CSW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman, President & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/14/2026S(1)1,500D$345.1574(2)64,236D
Common Stock3,219Iby ESOP
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Rights(3) (3) (3)Common Stock9,8369,836D
Performance Rights(4) (4) (4)Common Stock8,0048,004D
Performance Rights(5) (5) (5)Common Stock8,2368,236D
Performance Rights(6) (6) (6)Common Stock9,1869,186D
Restricted Stock Units(7) (7) (7)Common Stock19,68519,685D
Explanation of Responses:
1. The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 12, 2025.
2. The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $342.75 to $346.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 250% during a three-year performance cycle beginning on April 1, 2026 and ending on March 31, 2029 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
4. Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2025, and ending on March 31, 2028, based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
5. Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2024, and ending on March 31, 2027, based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
6. Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200%, during a performance cycle beginning April 1, 2021 and ending on March 31, 2027 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.
7. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at vesting. 40% of the restricted stock units vest no earlier than April 26, 2025 upon the successful recruitment and hiring of a successor Chief Executive Officer; the remaining 60% vest upon the successful first employment anniversary of a successor Chief Executive Officer.
Remarks:
/s/ Luke E. Alverson, Attorney-in-Fact for Joseph B. Armes08/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)